These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 26823828)

  • 1. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
    Yang J; Jiao S; Kang J; Li R; Zhang G
    Int J Clin Exp Pathol; 2015; 8(11):14959-64. PubMed ID: 26823828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancers.
    Oshima Y; Shimada H; Yajima S; Nanami T; Matsushita K; Nomura F; Kainuma O; Takiguchi N; Soda H; Ueda T; Iizasa T; Yamamoto N; Yamamoto H; Nagata M; Yokoi S; Tagawa M; Ohtsuka S; Kuwajima A; Murakami A; Kaneko H
    J Gastroenterol; 2016 Jan; 51(1):30-4. PubMed ID: 25906289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
    Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
    Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Case-Control Study: Smoking History Affects the Production of Tumor Antigen-Specific Antibodies NY-ESO-1 in Patients with Lung Cancer in Comparison with Cancer Disease-Free Group.
    Myšíková D; Adkins I; Hradilová N; Palata O; Šimonek J; Pozniak J; Kolařík J; Skallová-Fialová A; Špíšek R; Lischke R
    J Thorac Oncol; 2017 Feb; 12(2):249-257. PubMed ID: 27793776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens.
    Stockert E; Jäger E; Chen YT; Scanlan MJ; Gout I; Karbach J; Arand M; Knuth A; Old LJ
    J Exp Med; 1998 Apr; 187(8):1349-54. PubMed ID: 9547346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine-mapping naturally occurring NY-ESO-1 antibody epitopes in melanoma patients' sera using short overlapping peptides and full-length recombinant protein.
    Komatsu N; Jackson HM; Chan KF; Oveissi S; Cebon J; Itoh K; Chen W
    Mol Immunol; 2013 Jul; 54(3-4):465-71. PubMed ID: 23454162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum tumor-associated autoantibodies as diagnostic biomarkers for lung cancer: A systematic review and meta-analysis.
    Tang ZM; Ling ZG; Wang CM; Wu YB; Kong JL
    PLoS One; 2017; 12(7):e0182117. PubMed ID: 28750095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of Serum ELAVL4 (HuD) Antigen Assay for Small Cell Lung Cancer Diagnosis.
    Wang F; Lu J; Li S; Huo X; Liu X; Du X; Li C; Wang J; Chen Z
    Anticancer Res; 2017 Aug; 37(8):4515-4522. PubMed ID: 28739747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1.
    Türeci O; Mack U; Luxemburger U; Heinen H; Krummenauer F; Sester M; Sester U; Sybrecht GW; Sahin U
    Cancer Lett; 2006 May; 236(1):64-71. PubMed ID: 15992994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
    Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
    Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of serum proteins and multivariate models for diagnosis and therapeutic monitoring of lung cancer.
    Ma R; Xu H; Wu J; Sharma A; Bai S; Dun B; Jing C; Cao H; Wang Z; She JX; Feng J
    Oncotarget; 2017 Mar; 8(12):18901-18913. PubMed ID: 28121629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Application Value of Serum HE4 in the Diagnosis of Lung Cancer.
    Wang Y; Wang Z; Ding Y; Sun F; Ding X
    Asian Pac J Cancer Prev; 2019 Aug; 20(8):2405-2407. PubMed ID: 31450913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic and therapeutic value of progastrin-releasing peptide on small-cell lung cancer: A Single-Center Experience in China.
    Wu XY; Hu YB; Li HJ; Wan B; Zhang CX; Zhang B; Hu H; Zhang Q; Lv TF; Zhan P; Song Y
    J Cell Mol Med; 2018 Sep; 22(9):4328-4334. PubMed ID: 29989303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
    Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
    Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
    Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
    Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer.
    Doseeva V; Colpitts T; Gao G; Woodcock J; Knezevic V
    J Transl Med; 2015 Feb; 13():55. PubMed ID: 25880432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine antibody against human cancer antigen NY-ESO-1.
    Jäger D; Stockert E; Karbach J; Herrlinger K; Atmaca A; Arand M; Chen YT; Gnjatic S; Old LJ; Knuth A; Jäger E
    Cancer Immun; 2002 Aug; 2():10. PubMed ID: 12747755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NY-ESO-1 antibody as a novel tumour marker of gastric cancer.
    Fujiwara S; Wada H; Kawada J; Kawabata R; Takahashi T; Fujita J; Hirao T; Shibata K; Makari Y; Iijima S; Nishikawa H; Jungbluth AA; Nakamura Y; Kurokawa Y; Yamasaki M; Miyata H; Nakajima K; Takiguchi S; Nakayama E; Mori M; Doki Y
    Br J Cancer; 2013 Mar; 108(5):1119-25. PubMed ID: 23403818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
    Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.